To include your compound in the COVID-19 Resource Center, submit it here.

AZD1775: Phase II data

Data from 22 evaluable patients with p53-mutated refractory or resistant ovarian cancer in an open-label,

Read the full 156 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE